{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:10:59Z","timestamp":1792001459362,"version":"4.4.0"},"posted":{"date-parts":[[2023,7,25]]},"group-title":"Pharmacology and Toxicology","reference-count":69,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The gold standard pharmacological treatment for opioid use disorder (OUD) consists of maintenance therapy with long-acting opioid agonists such as buprenorphine and methadone. Despite these compounds having demonstrated substantial efficacy, a significant number of patients do not show optimal therapeutic responses. Moreover, the abuse liability of these medications remains a major concern. Cebranopadol, is a new, long-acting pan-opioid agonist that also activates the nociception\/orphanin FQ NOP receptor. Here we used rats to explore the therapeutic potential of this agent in OUD. First, in operant intravenous self-administration experiments we compared the potential abuse liability of cebranopadol with the prototypical opioid heroin. Under a fixed ratio 1 (FR1) contingency, rats maintained responding for heroin (1, 7, 20, 60 \u03bcg\/inf) to a larger extent than cebranopadol (0.03, 0.1, 0.3, 1.0, 6.0 \u03bcg\/inf). When the contingency was switched to a progressive ratio (PR) reinforcement schedule, heroin maintained responding at high levels at all except the lowest dose. Conversely, in the cebranopadol groups responding decreased drastically and the break point (BP) did not differ from saline controls. Next, we demonstrated that oral administration of cebranopadol (0, 25, 50 \u03bcg\/kg) significantly attenuated drug self-administration independent of heroin dose (1, 7, 20, 60 \u03bcg\/inf). Cebranopadol also reduced the break point for heroin (20 \u03bcg\/inf). Furthermore, in a heroin self-administration training extinction\/reinstatement paradigm, pretreatment with cebranopadol significantly attenuated yohimbine stress-induced reinstatement of drug seeking. Together, these data indicate that cebranopadol has limited abuse liability compared to heroin and is highly efficacious in attenuating opioid self-administration and stress-induced reinstatement, suggesting clinical potential of this compound for OUD treatment.<\/jats:p>","DOI":"10.1101\/2023.07.21.550008","type":"posted-content","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T12:25:21Z","timestamp":1690287921000},"source":"Crossref","is-referenced-by-count":1,"title":["Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy"],"prefix":"10.64898","author":[{"given":"Veronica","family":"Lunerti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Benvenuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Soverchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedbert","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023072713350467000_2023.07.21.550008v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd897"},{"key":"2023072713350467000_2023.07.21.550008v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00059-0"},{"key":"2023072713350467000_2023.07.21.550008v1.3","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620090-00001"},{"key":"2023072713350467000_2023.07.21.550008v1.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.7352279"},{"key":"2023072713350467000_2023.07.21.550008v1.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0485-1"},{"key":"2023072713350467000_2023.07.21.550008v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300712"},{"key":"2023072713350467000_2023.07.21.550008v1.7","first-page":"155","article-title":"Effects of buprenorphine on behaviour maintained by heroin and alfentanil in rhesus monkeys","volume":"7","year":"1996","journal-title":"Behav Pharmacol"},{"key":"2023072713350467000_2023.07.21.550008v1.8","doi-asserted-by":"publisher","DOI":"10.1111\/add.13238"},{"key":"2023072713350467000_2023.07.21.550008v1.9","doi-asserted-by":"crossref","unstructured":"Mattick RP , Breen C , Kimber J , Davoli M (2014): Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev.CD 002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"2023072713350467000_2023.07.21.550008v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30175-9"},{"key":"2023072713350467000_2023.07.21.550008v1.11","doi-asserted-by":"publisher","DOI":"10.2165\/00139709-200625020-00002"},{"key":"2023072713350467000_2023.07.21.550008v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.01.006"},{"key":"2023072713350467000_2023.07.21.550008v1.13","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003"},{"key":"2023072713350467000_2023.07.21.550008v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(00)00252-7"},{"key":"2023072713350467000_2023.07.21.550008v1.15","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.2.334"},{"key":"2023072713350467000_2023.07.21.550008v1.16","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.175620"},{"key":"2023072713350467000_2023.07.21.550008v1.17","doi-asserted-by":"publisher","DOI":"10.1021\/cn300124f"},{"key":"2023072713350467000_2023.07.21.550008v1.18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/adb.12513","article-title":"Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption","volume":"23","year":"2018","journal-title":"Addict Biol"},{"key":"2023072713350467000_2023.07.21.550008v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00590-2"},{"key":"2023072713350467000_2023.07.21.550008v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.10.029"},{"key":"2023072713350467000_2023.07.21.550008v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)01425-0"},{"key":"2023072713350467000_2023.07.21.550008v1.22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/ml500116x","article-title":"Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists","volume":"5","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"2023072713350467000_2023.07.21.550008v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeu332"},{"key":"2023072713350467000_2023.07.21.550008v1.24","doi-asserted-by":"publisher","DOI":"10.1021\/ml500117c"},{"key":"2023072713350467000_2023.07.21.550008v1.25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.213694"},{"key":"2023072713350467000_2023.07.21.550008v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(97)00599-6"},{"key":"2023072713350467000_2023.07.21.550008v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.188"},{"key":"2023072713350467000_2023.07.21.550008v1.28","first-page":"25","article-title":"Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine","volume":"262","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"2023072713350467000_2023.07.21.550008v1.29","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241042"},{"key":"2023072713350467000_2023.07.21.550008v1.30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fpsyt.2017.00234","article-title":"Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors","volume":"8","year":"2017","journal-title":"Front Psychiatry"},{"key":"2023072713350467000_2023.07.21.550008v1.31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/ALN.0000000000001529","article-title":"Respiratory Effects of the Nociceptin\/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers","volume":"126","year":"2017","journal-title":"Anesthesiology"},{"key":"2023072713350467000_2023.07.21.550008v1.32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/ALN.0000000000001530","article-title":"Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin\/Orphanin FQ Peptide Receptor Agonist Activity","volume":"126","year":"2017","journal-title":"Anesthesiology"},{"key":"2023072713350467000_2023.07.21.550008v1.33","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000995"},{"key":"2023072713350467000_2023.07.21.550008v1.34","first-page":"7451","article-title":"The use of bifunctional NOP\/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders","volume":"19","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2023072713350467000_2023.07.21.550008v1.35","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors - improved analgesics with reduced side effects?","volume":"175","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2023072713350467000_2023.07.21.550008v1.36","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00097-8","article-title":": Guidelines and methodological reviews concerning drug abuse liability assessment","volume":"70","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"2023072713350467000_2023.07.21.550008v1.37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/ALN.0000000000003848","article-title":"Functional Profile of Systemic and Intrathecal Cebranopadol in Nonhuman Primates","volume":"135","year":"2021","journal-title":"Anesthesiology"},{"key":"2023072713350467000_2023.07.21.550008v1.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0023-6"},{"key":"2023072713350467000_2023.07.21.550008v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2009.07.028"},{"key":"2023072713350467000_2023.07.21.550008v1.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2868-9"},{"key":"2023072713350467000_2023.07.21.550008v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2009.11.030"},{"key":"2023072713350467000_2023.07.21.550008v1.42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-016-4452-1","article-title":"Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents","volume":"234","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"2023072713350467000_2023.07.21.550008v1.43","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/s41386-022-01363-9","article-title":"Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies","volume":"47","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"2023072713350467000_2023.07.21.550008v1.44","first-page":"859","article-title":"Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain","volume":"8","year":"2015","journal-title":"J Pain Res"},{"key":"2023072713350467000_2023.07.21.550008v1.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022164"},{"key":"2023072713350467000_2023.07.21.550008v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12600-1"},{"key":"2023072713350467000_2023.07.21.550008v1.47","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2011.642758"},{"key":"2023072713350467000_2023.07.21.550008v1.48","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16070792"},{"key":"2023072713350467000_2023.07.21.550008v1.49","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2023072713350467000_2023.07.21.550008v1.50","doi-asserted-by":"crossref","unstructured":"Strain EC , Stitzer ML (2006): The treatment of opioid dependence. Baltimore: Johns Hopkins University Press.","DOI":"10.1345\/aph.1G682"},{"key":"2023072713350467000_2023.07.21.550008v1.51","doi-asserted-by":"crossref","unstructured":"Tzschentke TM , Kogel BY , Frosch S , Linz K (2017): Limited potential of cebranopadol to produce opioid-type physical dependence in rodents. Addict Biol.","DOI":"10.1111\/adb.12550"},{"key":"2023072713350467000_2023.07.21.550008v1.52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/j.pain.0000000000000986","article-title":"Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial","volume":"158","year":"2017","journal-title":"Pain"},{"key":"2023072713350467000_2023.07.21.550008v1.53","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.npp.1300435","article-title":"Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use","volume":"29","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"2023072713350467000_2023.07.21.550008v1.54","doi-asserted-by":"publisher","DOI":"10.1159\/000317070"},{"key":"2023072713350467000_2023.07.21.550008v1.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.10.004"},{"key":"2023072713350467000_2023.07.21.550008v1.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(99)00579-0"},{"key":"2023072713350467000_2023.07.21.550008v1.57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.26.14854"},{"key":"2023072713350467000_2023.07.21.550008v1.58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10444"},{"key":"2023072713350467000_2023.07.21.550008v1.59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2010.01392.x"},{"key":"2023072713350467000_2023.07.21.550008v1.60","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2400-13.2014"},{"key":"2023072713350467000_2023.07.21.550008v1.61","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-28-09445.2003"},{"key":"2023072713350467000_2023.07.21.550008v1.62","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-0985-7"},{"key":"2023072713350467000_2023.07.21.550008v1.63","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0262-6"},{"key":"2023072713350467000_2023.07.21.550008v1.64","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050608"},{"key":"2023072713350467000_2023.07.21.550008v1.65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506999102"},{"key":"2023072713350467000_2023.07.21.550008v1.66","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300487"},{"key":"2023072713350467000_2023.07.21.550008v1.67","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713000308"},{"key":"2023072713350467000_2023.07.21.550008v1.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.041"},{"key":"2023072713350467000_2023.07.21.550008v1.69","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000200"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.07.21.550008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:58:50Z","timestamp":1768453130000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.07.21.550008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1101\/2023.07.21.550008","relation":{},"subject":[],"published":{"date-parts":[[2023,7,25]]},"subtype":"preprint"}}